Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
6,171
datasets available to search
ShareScore release 0.9.0
Dataset results
6,171 results for “mutant”
Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators
ClinicalTrials.gov study NCT04732910. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC
ClinicalTrials.gov study NCT04028778. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
ClinicalTrials.gov study NCT05870319. IPD Sharing: Not stated. Countries: 1. Publications: 1.
IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
ClinicalTrials.gov study NCT03564821. IPD Sharing: NO. Countries: 1. Publications: 1.
Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
ClinicalTrials.gov study NCT02039336. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
ClinicalTrials.gov study NCT03972046. IPD Sharing: NO. Countries: 1. Publications: 10.
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
ClinicalTrials.gov study NCT03383575. IPD Sharing: Not stated. Countries: 1. Publications: 1.
IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
ClinicalTrials.gov study NCT03515512. IPD Sharing: NO. Countries: 1. Publications: 2.
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
ClinicalTrials.gov study NCT02858921. IPD Sharing: NO. Countries: 1. Publications: 2.
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
ClinicalTrials.gov study NCT04117087. IPD Sharing: NO. Countries: 1. Publications: 0.
Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer
ClinicalTrials.gov study NCT03827044. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
ClinicalTrials.gov study NCT02036086. IPD Sharing: YES. Countries: 1. Publications: 16.
First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene
ClinicalTrials.gov study NCT00339586. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC
ClinicalTrials.gov study NCT07294261. IPD Sharing: NO. Countries: 1. Publications: 3.
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
ClinicalTrials.gov study NCT05067283. IPD Sharing: YES. Countries: 21. Publications: 1.
Olaparib in Recurrent IDH-mutant Glioma
ClinicalTrials.gov study NCT03561870. IPD Sharing: NO. Countries: 1. Publications: 1.
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
ClinicalTrials.gov study NCT05921760. IPD Sharing: YES. Countries: 2. Publications: 0.
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
ClinicalTrials.gov study NCT04835805. IPD Sharing: YES. Countries: 5. Publications: 1.
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
ClinicalTrials.gov study NCT06128551. IPD Sharing: NO. Countries: 7. Publications: 1.
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
ClinicalTrials.gov study NCT05501912. IPD Sharing: NO. Countries: 1. Publications: 22.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.